ASCO 2017 | What is the future of treating ALL?

Susan O’Brien

Susan O’Brien, MD from the University of California, Irvine, CA discusses the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. Referencing two studies evaluating the effectiveness of ponatinib or inotuzumab ozogamicin with low-dose chemotherapy in treating ALL (NCT00671658) (NCT01230788), she notes that both trials had promising results and the future for ALL treatment appears to be positive.

Share this video